RARE vs BIIB Stock Comparison: AI Score, Valuation, Performance and Upside
Ultragenyx and Biogen represent different stages of biotechnology maturity, with Ultragenyx pursuing a still-developing rare disease pipeline with ongoing cash burn, while Biogen operates an established, revenue-generating neuroscience franchise navigating its own competitive and commercial adoption challenges.
Ultragenyx offers exposure to a higher-risk, earlier-stage rare disease pipeline with multiple approval catalysts, while Biogen offers exposure to an established neuroscience franchise with more predictable, if pressured, revenue streams. Consider whether you prefer Ultragenyx's pipeline growth potential or Biogen's established franchise stability.
BIIB holds the edge across 4 of 5 key metrics in this comparison. BIIB leads on both 1-year return (+55.93%) and forward P/E quality (13.21x vs 39.86x for RARE), a relatively favorable combination of momentum and valuation. On fundamentals, RARE is growing revenue faster (28.10%), while BIIB maintains the higher operating margin (25.06%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for RARE (+108.30%) than for BIIB (+8.11%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Believe a diversified pipeline across multiple rare and ultra-rare genetic disease programs offers significant upside potential
- Are comfortable with continued cash burn during the path toward sustained profitability
- Value specialized rare disease development expertise and orphan drug regulatory navigation
- Are willing to accept higher risk in exchange for multiple pipeline approval catalysts
- Want exposure to an established neuroscience treatment franchise spanning multiple sclerosis and Alzheimer's disease
- Believe Alzheimer's disease treatment adoption will continue improving over time
- Value diversified pipeline exposure across multiple neurological and rare disease indications
- Prefer an established, revenue-generating biopharmaceutical company over an earlier-stage pipeline story
| Metric | RARE | BIIB |
|---|---|---|
| AI scorei | 25.6 | 29.0 |
| AI ranki | #2748 | #2338 |
| Latest closei | $15.30 | $220.83 |
| 1M returni | -38.63% | +6.87% |
| 6M returni | -28.70% | +17.41% |
| 1Y returni | -51.51% | +55.93% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | RARE | BIIB |
|---|---|---|
| 1Y ago | $4.89K (-51.1%) started 2025-09-04 | $15.78K (+57.8%) started 2025-09-04 |
| 5Y ago | $1.5K (-85.0%) started 2021-09-07 | $6.75K (-32.5%) started 2021-09-07 |
| 10Y ago | $2.27K (-77.3%) started 2016-09-06 | $7.11K (-28.9%) started 2016-09-06 |
Hypothetical — past performance does not guarantee future results.
| Metric | RARE | BIIB |
|---|---|---|
| Market capi | $2.62B | $32.28B |
| Trailing P/Ei | N/A | 38.74 |
| Forward P/Ei | 39.86 | 13.21 |
| Price/Salesi | N/A | 1.99 |
| EV/Revenuei | 4.92 | 3.92 |
| Analyst targeti | $55.26 | $236.22 |
| Target upsidei | +108.30% | +8.11% |
| Metric | RARE | BIIB |
|---|---|---|
| Revenue growthi | 28.10% | 3.40% |
| Earnings growthi | N/A | -84.80% |
| EPS growthi | N/A | -84.80% |
| FCF margini | -25.08% | +12.63% |
| Operating margini | -35.05% | 25.06% |
| Profit margini | -81.73% | 8.32% |
| ROIC proxyi | N/A | 4.58% |
| Return on equityi | N/A | 4.58% |
| Dividend yieldi | N/A | N/A |
| Betai | 0.31 | 0.16 |
| Debt/equityi | N/A | 44.33 |
| Current ratioi | 1.73 | 1.86 |
| Quick ratioi | 1.41 | 0.94 |
Over the past year, RARE and BIIB have moved barely in the same direction (correlation of 0.13), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | RARE | BIIB |
|---|---|---|---|
| 1Y | Growthi | -51.09% | +57.80% |
| CAGRi | -51.14% | +57.91% | |
| Volatilityi | 80.22% | 35.01% | |
| Sharpe ratioi | -0.45 | 1.35 | |
| Sortino ratioi | -0.52 | 2.17 | |
| Max drawdowni | 59.36% | 14.34% | |
| Current drawdowni | 58.13% | 1.64% | |
| Avg drawdowni | 23.68% | 4.88% | |
| Ulcer Indexi | 28.10% | 5.91% | |
| Max daily dropi | 44.03% | 8.17% | |
| Max wkly dropi | 43.45% | 12.37% | |
| 5Y | Growthi | -85.00% | -32.52% |
| CAGRi | -31.62% | -7.58% | |
| Volatilityi | 57.83% | 34.73% | |
| Sharpe ratioi | -0.42 | -0.19 | |
| Sortino ratioi | -0.53 | -0.31 | |
| Max drawdowni | 85.48% | 65.35% | |
| Current drawdowni | 85.04% | 32.52% | |
| Avg drawdowni | 56.17% | 34.79% | |
| Ulcer Indexi | 58.35% | 38.11% | |
| Max daily dropi | 44.03% | 8.17% | |
| Max wkly dropi | 43.45% | 13.62% | |
| 10Y | Growthi | -77.29% | -28.92% |
| CAGRi | -13.79% | -3.36% | |
| Volatilityi | 56.84% | 41.37% | |
| Sharpe ratioi | -0.04 | 0.01 | |
| Sortino ratioi | -0.05 | 0.01 | |
| Max drawdowni | 91.63% | 72.66% | |
| Current drawdowni | 91.37% | 46.75% | |
| Avg drawdowni | 52.22% | 34.55% | |
| Ulcer Indexi | 58.37% | 39.08% | |
| Max daily dropi | 44.03% | 29.23% | |
| Max wkly dropi | 43.45% | 34.30% |
| Category | RARE | BIIB |
|---|---|---|
| Company | Ultragenyx Pharmaceutical Inc. | Biogen Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Core business | A biotechnology company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases, with a growing portfolio of approved products and a broader clinical-stage pipeline. | A biopharmaceutical company focused on neuroscience treatments, including multiple sclerosis and Alzheimer's disease therapies, alongside a broader pipeline spanning rare disease and other neurological conditions. |
| Investor focus | Approved product portfolio revenue growth, clinical pipeline progress across multiple rare disease programs, and path toward sustained profitability as the commercial portfolio matures. | Alzheimer's disease treatment commercial adoption trends, multiple sclerosis franchise stability amid competitive pressure, and pipeline progress across other neuroscience indications. |
- Diversified pipeline across multiple rare and ultra-rare genetic disease programs offers numerous potential future approval catalysts
- Growing portfolio of approved products provides increasing commercial revenue supporting continued pipeline investment
- Specialized rare disease development expertise supports efficient navigation of orphan drug regulatory pathways
- Established position in neuroscience treatment provides deep physician relationships and disease-area expertise
- Alzheimer's disease treatment franchise offers exposure to a large, underserved patient population with significant unmet medical need
- Diversified neuroscience pipeline spans multiple sclerosis, Alzheimer's, and other neurological and rare disease indications
- Continued cash burn from pipeline investment requires successful commercial execution to reach sustained profitability
- Rare and ultra-rare disease focus means individual product revenue potential is inherently limited by very small patient populations
- Clinical pipeline programs carry substantial execution risk given the inherent uncertainty of rare disease drug development
- Multiple sclerosis franchise faces ongoing competitive pressure and biosimilar competition affecting legacy product revenue
- Alzheimer's disease treatment commercial adoption has faced challenges related to reimbursement, administration complexity, and market uptake pace
- Pipeline execution across neuroscience indications carries substantial clinical trial and regulatory risk
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.